ADAM SETH MEDNICK MD PHD
Prescription History 1922015643
Psychiatry & Neurology - Neurology in Vincennes, IN

NPI Status: Active since August 02, 2006

Contact Information

328 N 2ND ST STE 301
VINCENNES, IN
ZIP 47591
Phone: (812) 885-6850
Fax: (812) 885-6851

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for ADAM SETH MEDNICK MD PHD, an active Neurology specialist practicing in Vincennes, IN. Our medical registry currently tracks 13 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 256 documented patient claims. Among these therapy options, the most frequently utilized medication is Carbidopa-Levodopa, which accounts for 38 claims alone.


Amitriptyline Hcl

Generic Formulation: Amitriptyline HclSpecialty: Neurology
Provider Metrics Summary
Total Claims 13
30-Day Fills 21.3
Days Supply 628
IN State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills54.4
Peer Average Days Supply1,607
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 53.6% less volume than the regional standard for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $370.92 across this reporting matrix range.

Provider Avg Cost Per Claim

$28.53

State Avg Cost Per Claim

$22.30

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat mental/mood problems such as depression. It may help improve mood and feelings of well-being, relieve anxiety and tension, help you sleep better, and increase your energy level. This medication belongs to a class of medications called tricyclic antidepressants. It works by affecting the balance of certain natural chemicals (neurotransmitters such as serotonin) in the brain.

Baclofen

Generic Formulation: BaclofenSpecialty: Neurology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
IN State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills58.5
Peer Average Days Supply1,576
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 73.2% less volume than the regional standard for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $536.91 across this reporting matrix range.

Provider Avg Cost Per Claim

$48.81

State Avg Cost Per Claim

$32.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A GAMMA-AMINOBUTYRIC ACID derivative that is a specific agonist of GABA-B RECEPTORS. It is used in the treatment of MUSCLE SPASTICITY, especially that due to SPINAL CORD INJURIES. Its therapeutic effects result from actions at spinal and supraspinal sites, generally the reduction of excitatory transmission.

Therapeutic Applications

Baclofen is used to treat muscle spasms caused by certain conditions (such as multiple sclerosis, spinal cord injury/disease). It works by helping to relax the muscles.

Carbidopa-Levodopa

Generic Formulation: Carbidopa/LevodopaSpecialty: Neurology
Provider Metrics Summary
Total Claims 38
30-Day Fills 47.1
Days Supply 1,401
IN State Average Benchmarks
Peer Average Claims62.0
Peer Average 30-Day Fills101.9
Peer Average Days Supply2,772
Conservative Utilization

This provider writes prescriptions for this formulation 38.7% less frequently than the standard regional baseline metric for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $441.05 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.61

State Avg Cost Per Claim

$43.26

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination medication is used to treat symptoms of Parkinson's disease or Parkinson-like symptoms (such as shakiness, stiffness, difficulty moving). Parkinson's disease is thought to be caused by too little of a naturally occurring substance (dopamine) in the brain. Levodopa changes into dopamine in the brain, helping to control movement. Carbidopa prevents the breakdown of levodopa in the bloodstream so more levodopa can enter the brain. Carbidopa can also reduce some of levodopa's side effects such as nausea and vomiting.

Emgality Pen

Generic Formulation: Galcanezumab-GnlmSpecialty: Neurology
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 450
IN State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills35.5
Peer Average Days Supply1,043
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $11,489.22 across this reporting matrix range.

Provider Avg Cost Per Claim

$765.95

State Avg Cost Per Claim

$862.94

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to help prevent migraine. It is also used to treat a certain type of headache (episodic cluster headache). Galcanezumab belongs to a class of drugs known as monoclonal antibodies. This medication may work by changing the amounts of certain natural substances in the brain. Using this medication can help improve your ability to concentrate and do your usual tasks.

Gabapentin

Generic Formulation: GabapentinSpecialty: Neurology
Provider Metrics Summary
Total Claims 23
30-Day Fills 29.0
Days Supply 858
IN State Average Benchmarks
Peer Average Claims107.0
Peer Average 30-Day Fills170.0
Peer Average Days Supply4,888
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 78.5% less volume than the regional standard for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $432.17 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.79

State Avg Cost Per Claim

$20.83

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Lacosamide

Generic Formulation: LacosamideSpecialty: Neurology
Provider Metrics Summary
Total Claims 29
30-Day Fills 29.0
Days Supply 774
IN State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills40.6
Peer Average Days Supply1,073
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,788.91 across this reporting matrix range.

Provider Avg Cost Per Claim

$165.13

State Avg Cost Per Claim

$282.79

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An acetamide derivative that acts as a blocker of VOLTAGE-GATED SODIUM CHANNELS. It is used as an anticonvulsant, for adjunctive or monotherapy, in the treatment of PARTIAL SEIZURES.

Therapeutic Applications

Lacosamide is used to prevent and control seizures. It is an anticonvulsant or antiepileptic drug. It works by reducing the spread of seizure activity in the brain.

Levetiracetam

Generic Formulation: LevetiracetamSpecialty: Neurology
Provider Metrics Summary
Total Claims 29
30-Day Fills 39.0
Days Supply 1,166
IN State Average Benchmarks
Peer Average Claims58.0
Peer Average 30-Day Fills89.8
Peer Average Days Supply2,444
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $718.01 across this reporting matrix range.

Provider Avg Cost Per Claim

$24.76

State Avg Cost Per Claim

$39.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrrolidinone and acetamide derivative that is used primarily for the treatment of SEIZURES and some movement disorders, and as a nootropic agent.

Therapeutic Applications

Levetiracetam is used to treat seizures (epilepsy). It belongs to a class of drugs known as anticonvulsants. Levetiracetam may decrease the number of seizures you have.

Pregabalin

Generic Formulation: PregabalinSpecialty: Neurology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
IN State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills59.5
Peer Average Days Supply1,709
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 76.1% less volume than the regional standard for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $78.91 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.17

State Avg Cost Per Claim

$47.21

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A gamma-aminobutyric acid (GABA) derivative that functions as a CALCIUM CHANNEL BLOCKER and is used as an ANTICONVULSANT as well as an ANTI-ANXIETY AGENT. It is also used as an ANALGESIC in the treatment of NEUROPATHIC PAIN and FIBROMYALGIA.

Therapeutic Applications

This medication is used to treat pain caused by nerve damage due to diabetes, shingles (herpes zoster) infection, or spinal cord injury. This medication is also used to treat pain in people with fibromyalgia. It is also used with other medications to treat certain types of seizures (focal seizures).

Propranolol Hcl

Generic Formulation: Propranolol HclSpecialty: Neurology
Provider Metrics Summary
Total Claims 13
30-Day Fills 15.3
Days Supply 459
IN State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills43.9
Peer Average Days Supply1,264
Conservative Utilization

This provider writes prescriptions for this formulation 45.8% less frequently than the standard regional baseline metric for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $105.77 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.14

State Avg Cost Per Claim

$26.22

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This formulation of propranolol is used for infants and children to treat a certain benign tumor (proliferating infantile hemangioma). It helps to shrink the tumor. Propranolol belongs to a class of drugs known as beta blockers.

Tizanidine Hcl

Generic Formulation: Tizanidine HclSpecialty: Neurology
Provider Metrics Summary
Total Claims 18
30-Day Fills 19.0
Days Supply 570
IN State Average Benchmarks
Peer Average Claims45.0
Peer Average 30-Day Fills63.7
Peer Average Days Supply1,719
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 60.0% less volume than the regional standard for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $423.48 across this reporting matrix range.

Provider Avg Cost Per Claim

$23.53

State Avg Cost Per Claim

$18.54

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat muscle spasms caused by certain conditions (such as multiple sclerosis, spinal cord injury). It works by helping to relax the muscles.

Topiramate

Generic Formulation: TopiramateSpecialty: Neurology
Provider Metrics Summary
Total Claims 31
30-Day Fills 43.0
Days Supply 1,290
IN State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills61.9
Peer Average Days Supply1,795
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $548.73 across this reporting matrix range.

Provider Avg Cost Per Claim

$17.70

State Avg Cost Per Claim

$18.02

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A sulfamate-substituted fructose analog that was originally identified as a hypoglycemic agent. It is used for the treatment of EPILEPSY and MIGRAINE DISORDERS, and may also promote weight loss.

Therapeutic Applications

Topiramate is used alone or with other medications to prevent and control seizures (epilepsy). This medication is also used to prevent migraine headaches and decrease how often you get them. Topiramate will not treat a migraine headache once it occurs. If you get a migraine headache, treat it as directed by your doctor (such as by taking pain medication, lying down in a dark room). Topiramate is known as an anticonvulsant or antiepileptic drug.

Tramadol Hcl

Generic Formulation: Tramadol HclSpecialty: Neurology
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 370
IN State Average Benchmarks
Peer Average Claims59.0
Peer Average 30-Day Fills60.1
Peer Average Days Supply1,211
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 76.3% less volume than the regional standard for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $182.33 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.02

State Avg Cost Per Claim

$7.94

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A narcotic analgesic proposed for severe pain. It may be habituating.

Therapeutic Applications

See also Warning section. This medication is used to help relieve moderate to moderately severe pain. Tramadol belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain.

Zonisamide

Generic Formulation: ZonisamideSpecialty: Neurology
Provider Metrics Summary
Total Claims 11
30-Day Fills 15.0
Days Supply 434
IN State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills52.0
Peer Average Days Supply1,480
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 64.5% less volume than the regional standard for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $190.63 across this reporting matrix range.

Provider Avg Cost Per Claim

$17.33

State Avg Cost Per Claim

$41.36

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.

Therapeutic Applications

Zonisamide is used with other medications to prevent and control seizures (epilepsy). Zonisamide is a sulfonamide anticonvulsant and a carbonic anhydrase inhibitor. It is unknown how zonisamide works to prevent seizures.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like ADAM SETH MEDNICK MD PHD provides transparency into local medical care patterns within Vincennes, IN.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Neurology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.